The business model of Neuropace Inc involves developing and commercializing medical devices to treat neurological disorders. Specializing in responsive neurostimulation, the company's flagship product is the RNS® System. This implantable device, approved by the FDA, is designed to detect abnormal electrical brain activity and deliver therapeutic electrical pulses to the affected area, aiming to reduce seizures in patients with epilepsy. By providing innovative technology and comprehensive support, Neuropace Inc aims to improve the quality of life for individuals suffering from refractory epilepsy.

Neuropace Inc is primarily active in the medical device industry.

The main competitors of Neuropace Inc in the market include Medtronic, Cyberonics, and Boston Scientific.

NeuroPace Inc is a leading medical technology company focused on providing innovative solutions for the treatment of neurological disorders. Founded in 1997, the company has been dedicated to developing responsive neurostimulation systems. Their flagship product, RNS System, is the world's first and only FDA-approved brain-responsive neurostimulator for the treatment of epilepsy. With a commitment to improving the quality of life for patients with uncontrolled seizures, NeuroPace Inc continues to advance the field of neuromodulation. Their groundbreaking technology offers hope and relief to individuals who have not responded well to traditional epilepsy treatments.

Neuropace Inc has achieved several significant milestones. The company successfully developed and received FDA approval for the RNS System, a novel medical device for treating epilepsy. This innovative device has revolutionized the treatment landscape for patients with drug-resistant focal epilepsy. Neuropace Inc has also made remarkable strides in research and development, continually enhancing their technology and expanding its applications. Furthermore, the company has established collaborations with renowned medical centers worldwide, further validating the efficacy and safety of their products. With these notable achievements, Neuropace Inc has solidified its position as a leader in the field of neurostimulation therapies for patients suffering from epilepsy.

Neuropace Inc is primarily present in the United States.

Neuropace Inc represents values of innovation, patient-centered care, and commitment to improving the lives of individuals with neurological disorders. The company focuses on developing innovative medical technologies to address unmet medical needs in the field of epilepsy management. With a corporate philosophy centered on offering personalized and advanced treatment options, Neuropace Inc aims to empower patients and healthcare professionals in their battle against epilepsy. By leveraging cutting-edge neurostimulation technology and continuous monitoring, the company strives to provide effective solutions for better seizure control and enhanced quality of life for epilepsy patients.

Analysts currently set an average price target of 19,89 USD for the Neuropace stock (median: 20,40 USD), implying +35,5 % versus the latest price. The consensus is based on 14 analyst ratings.

Neuropace Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Neuropace stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuropace to generate revenue of 99,99 M USD and earnings per share of −0,57 USD.

Neuropace Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Neuropace share trades at 12,90 EUR (14,68 USD).

The Neuropace share (NPCE) is listed on 1 stock exchanges, including: NASDAQ (NPCE).

The company Neuropace Inc. specializes in manufacturing and distributing medical devices. It was founded in 1997 and is based in Mountain View, California. Its main focus is on developing implantable medical devices for the treatment of epilepsy. Neuropace Inc.'s main expertise is in the production of neurostimulators. These devices are implanted directly in the brain and deliver targeted impulses that can reduce or even prevent epilepsy seizures. The technology used in these neurostimulators was developed and patented by Neuropace itself. Neuropace's neurostimulators are capable of detecting seizures in patients and then initiating targeted brain stimulation to interrupt the seizure. The devices can therefore be considered a kind of "emergency shutdown" for the brain. In addition, the devices can also be used for seizure prevention by continuously emitting signals to keep the brain calm. In addition to developing and manufacturing neurostimulators, Neuropace also offers clinical services. The company is actively involved in conducting clinical trials to investigate the safety and efficacy of neurostimulators. It also provides training for medical professionals to properly implant the device and care for patients. Neuropace's business model is based on the manufacture and sale of neurostimulators and the provision of clinical services. The company operates a direct sales model and sells its products directly to medical professionals and hospitals. The company also engages in active research and development to continuously improve the effectiveness of its products and bring new products to the market. The company operates globally. Its products are approved and focused in the US, Canada, and Europe, with plans to obtain further approvals in other parts of the world due to high demand. It is expected that the company is planning extensive expansions. Overall, Neuropace is an innovative company specializing in the development of novel medical devices that can help improve the quality of life for people with epilepsy. With its unique technology and emphasis on ensuring the highest possible safety and efficacy of its devices, Neuropace has achieved a leading position in the market and plans to continue growing in the future.

odotettu liikevaihto Neuropace on 99,99 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Neuropace on −18,53 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Neuropace:n hinta-voitto-suhde (P/E) on tällä hetkellä −25,92. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Neuropace-osakkeen arvostusta.

Neuropace:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,80. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Neuropace-osakkeen arvostuskennuslukuna.

Neuropace:n Eulpool-laatuscore on 3/10.

Neuropace:n ISIN on US6412881053. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Neuropace:n ticker on NPCE. Tämä pörssinoteeraus käytetään Neuropace-osakkeiden kauppaan pörssissä.

Neuropace maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Neuropace kuuluu sektoriin 'Terveydenhuolto'.

Neuropace:n osingot jaetaan valuutassa USD.